(AOF) – On the occasion of the presentation of its 2023 results, Innate Pharma specifies that its cash position was 102.3 million euros as of December 31, 2023 – this amount not taking into account the payment from Sanofi of 15 million euros collected in January – and the cash horizon extends until the end of 2025. The biotech shows a net loss of 7.6 million euros in 2023 compared to a net loss of 58.1 million euros euros in 2022.
Operating income relating to continuing activities amounts to 61.6 million euros in 2023, an increase of 6.9%. This mainly concerns income from collaboration and licensing agreements and the research tax credit.
“In 2024, we expect several important milestones including the results of the Tellomak Phase 2 study of lacutamab in mycosis fungoides and the filing of the clinical study application (IND) for IPH45, our first antibody-drug conjugate (ADC ).” declared Hervé Brailly, interim chairman of the management board of Innate Pharma.
© 2024 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
